<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049591</url>
  </required_header>
  <id_info>
    <org_study_id>HD PCI</org_study_id>
    <nct_id>NCT04049591</nct_id>
  </id_info>
  <brief_title>Higher vs. Lower Dose Heparin for PCI</brief_title>
  <acronym>HD-PCI</acronym>
  <official_title>A Randomized Trial of Higher vs. Lower Dose Heparin for PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher
      dose versus lower dose heparin in patients undergoing elective percutaneous coronary
      intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of HD PCI is to compare the effect of a policy of higher dose heparin
      (100 U/kg) use to a policy of lower dose heparin (70 U/kg) use on death, myocardial
      infarction (MI) or target vessel revascularization (TVR) in patients undergoing elective
      percutaneous coronary intervention (PCI).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Cluster crossover</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with any of the following: death, myocardial infarction or target vessel revascularization</measure>
    <time_frame>up to 30 days after PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with major bleeding</measure>
    <time_frame>up to 30 days after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with any of the following: death, myocardial infarction, target vessel revascularization or major bleeding</measure>
    <time_frame>up to 30 days after PCI</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with either of the following: death or myocardial infarction</measure>
    <time_frame>up to 30 days after PCI</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants with definite stent thrombosis</measure>
    <time_frame>up to 30 days after PCI</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16000</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Higher Dose Unfractionated Heparin Treatment Period</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A centre wide policy of administering 100 U/kg bolus of intravenous unfractionated heparin (UFH) for elective percutaneous coronary intervention (PCI) procedures will be implemented during the Higher Dose UFH treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower Dose Unfractionated Heparin Treatment Period</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures will be implemented during the Lower Dose UFH treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher Dose UFH</intervention_name>
    <description>Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures</description>
    <arm_group_label>Higher Dose Unfractionated Heparin Treatment Period</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lower Dose UFH</intervention_name>
    <description>Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures</description>
    <arm_group_label>Lower Dose Unfractionated Heparin Treatment Period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients undergoing elective PCI

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Planned chronic total occlusion PCI

          -  Non-resident precluding follow up through local registries

        Hospital (Cluster) Eligibility Criteria

        Hospitals will be eligible to participate if they meet the following criteria:

          -  Submit PCI procedure data to a compatible registry that is able to provide data for
             the trial

          -  Site agrees to manage patients as per the higher or lower dose heparin policy in place
             during the given crossover period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjit Jolly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Research Coordinator</last_name>
    <phone>9055122100</phone>
    <email>HD-PCI@phri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton Health Sciences, General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Principal Investigator, MD</last_name>
      <email>HD-PCI@phri.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

